-
Meet the Organix Director, Mario Gonzalez
We are pleased to share a conversation with Dr. Mario Gonzalez, a Director at Organix, as he reflects on his journey from Argentina to Massachusetts and provides valuable career insights in celebration of his 30 years with the company.
-
New Production Lines D1 and D2 at our Prague site!
The new production lines D1 and D2 were launched for the first time in May 2024 at the Prague site. The first batch of 11 kg of API was produced in the following weeks, and the tremendous efforts of the many people involved in planning the entire production line have finally paid off. Since the production line was launched, all equipment has been continuously utilized.
-
Reliable Tablet Formulation at Exemplify!
We at Symeres pride ourselves on a stellar track record in drug-substance development. For our clients that are looking to rapidly move through phase-appropriate clinical tablet formulation development, Exemplify is the perfect place to start for small-scale to large-scale pharma companies. Our cGMP suites are specially equipped to support everything from pre-tox formulation to first-in-human (FIH) trials and commercially ready formulation.
-
Peter Molenveld’s 25th Anniversary with Symeres
Recently, our colleague Peter Molenveld celebrated his 25th anniversary with Symeres. Peter participated in an interview where he shared about his time with Symeres and his growth here as a chemist to leadership within the organization, as well as about his role as secretary at the Royal Netherlands Chemical Society (KNCV).
Latest patents
-
Novel intermediate in production of oxoisoquinoline derivative with BTK inhibitory activity
Number: WO2024134859 (PCT/JP2022/047526)
-
Compounds and their use as PDE4 activators
Number: WO/2024/038129
-
Compounds and their use as PDE4 activators
Number: WO/2024/038128
Latest publications
-
Silicon-based Linkers for Tunable Acid-Sensitive Drug Release from Polymeric Nanoparticles
Article: Chemistry Europe. 2024 Dec 11:e202403589
-
Rare Case of Polymorphism in the Binary System of Enantiomers of a Praziquantel Derivative
Article: Org. Process Res. Dev. 2024, 28, 4, 1224–1232
-
Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ-1 Subunit of Voltage-Gated Calcium Channel and the μ-Opioid Receptor
Article: ChemMedChem 2024, e202300473
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
